Entera Bio Ltd.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of orally delivered large molecule therapeutics, including peptides and therapeutic proteins. The company's core mission is to address significant unmet medical needs by transforming injectable treatments into convenient oral tablet forms, thereby aiming to improve patient adherence and health outcomes. Entera Bio's principal executive offices are located in Jerusalem, Israel, with a U.S. headquarters established in Wellesley, Massachusetts, to support financial, business development, and clinical/regulatory functions.

Entera Bio leverages its proprietary N-Tab® oral delivery technology platform to stabilize peptides in the gastrointestinal tract and enhance their systemic absorption. The company's pipeline includes several key product candidates: EB613, an oral parathyroid hormone (PTH) analog currently in a Phase 3 registrational study for post-menopausal women with osteoporosis; and EB612, an oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism, which has received orphan drug designation. Additionally, through a collaboration with OPKO Health, Entera Bio is developing an oral GLP-1/glucagon peptide for obesity and metabolic disorders, and an oral GLP-2 peptide for short bowel syndrome.

Recent notable developments include the appointment of Geno J. Germano as Chairman of the Board in February 2026, succeeding Gerald Lieberman. In April 2026, Entera Bio announced a $10 million private placement, with potential for additional proceeds, to fund the initiation of the Phase 3 EB613 study. The company also submitted a streamlined Phase 3 protocol for EB613 to the FDA in March 2026. Furthermore, Entera Bio expanded its partnership with OPKO Health in February 2026 to advance a first-in-class oral long-acting PTH tablet for hypoparathyroidism, with an Investigational New Drug (IND) application targeted for late 2026.